Therapeutic strategies have been developed to target the role of Galectin-1, including small-molecule and mAb Gal-1 inhibitors and positron emission tomography imaging for noninvasive profiling of tumor microenvironment. This evidence concerns the gene LGALS1 and neoplasm.